O le Janssen Pharmaceutical Companies a Johnson & Johnson i aso nei na faʻasalalau ai le US Food and Drug Administration (FDA) ua faʻamaonia le faʻalauteleina o igoa mo CABENUVA (rilpivirine ma cabotegravir) e faʻatinoina i masina taʻi lua mo le togafitia o le HIV-1 i tagata matutua faʻamaʻi (HIV). -1 RNA e itiiti ifo i le 50 kopi i le milliliter [c/ml]) i luga o se faʻatonuga mautu, e leai se talaʻaga o togafitiga faʻaletonu, ma e aunoa ma se iloa pe masalomia le tetee i le rilpivirine poʻo le cabotegravir.

eTurboNews tala e mo na'o le au fai saofaga. O le lesitala o saʻoloto.
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE

OA MEA E AVEA MAI LENEI TUSI:

Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir.
.
eTurboNews tala e mo na'o le au fai saofaga.